Antoine Papiernik (Sofinnova)

Sofinno­va hauls in $548M to build and scale star­tups — as Eu­ro­pean VCs step up their bio­phar­ma game

When Sofinno­va Part­ners un­veiled its $540 mil­lion crossover fund ear­li­er this year, the Paris-based pow­er VC play­er tout­ed its lead­ing role in pro­vid­ing late-stage cap­i­tal to high-growth star­tups in Eu­rope and be­yond.

But that doesn’t mean it’s for­get­ting its roots in ear­ly-stage health­care in­vest­ing.

In fact, the Sofinno­va crew was al­ready talk­ing to in­vestors be­hind the scenes for what would be­come the largest it­er­a­tion yet of its flag­ship fund. At $548 mil­lion (€472 mil­lion), Sofinno­va Cap­i­tal X is al­most $50 mil­lion big­ger than its pre­de­ces­sor and brings its to­tal as­sets un­der man­age­ment to more than €2.5 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.